Published on, Aug. 25 -- August 25, 2025 5:21 PM

US health authorities have suspended the licence of the Ixchiq vaccine, used against the mosquito-borne chikungunya virus, after reports of serious side effects in several patients, including elderly individuals. The vaccine, developed by French company Valneva, had been approved by the US Food and Drug Administration (FDA) in 2023 but is now under strict review following the latest concerns.

Valneva confirmed that the FDA's suspension took immediate effect on Friday after four new cases of severe side effects were reported. Three of these cases involved patients aged between 70 and 82, raising questions about the vaccine's safety for older age groups. The decision follows earlier reviews...